Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 18/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2887622 | 0.99 | PDE4A (0.50) | PDE4APDE4DPDE4BPDE4CMEN1 | |
| SCHEMBL2887619 | 0.99 | PDE4A (0.50) | PDE4APDE4DPDE4BPDE4CMEN1 | |
| SCHEMBL2887615 | 0.99 | PDE4A (0.50) | PDE4APDE4DPDE4BPDE4CMEN1 | |
| SCHEMBL5733765 | 0.83 | PDE4D (0.42) | PDE4APDE4DPDE4BPDE4CMEN1 | |
| SCHEMBL2888513 | 0.83 | PDE4D (0.46) | PDE4APDE4DPDE4BPDE4CMEN1 | |
| SCHEMBL2888511 | 0.83 | PDE4D (0.46) | PDE4APDE4DPDE4BPDE4CMEN1 | |
| SCHEMBL2881657 | 0.83 | PDE4D (0.46) | PDE4APDE4DPDE4BPDE4CMEN1 | |
| SCHEMBL2881663 | 0.83 | PDE4D (0.46) | PDE4APDE4DPDE4BPDE4CMEN1 | |
| SCHEMBL2888509 | 0.83 | PDE4D (0.46) | PDE4APDE4DPDE4BPDE4CMEN1 | |
| SCHEMBL2881661 | 0.83 | PDE4D (0.46) | PDE4APDE4DPDE4BPDE4CMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776893-B2 | Use of PDE4 inhibitors for the treatment of diabetes mellitus | NYCOMED GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20060281745-A1 | Use of pde4 inhibitors for the treatment of diabetes mellitus | ALTANA PHARMA AG (DE) | 2006-12-14 | — | — | US | disclosed |
| EP-1650193-A2 | 6-Phenylphenanthridines with PDE-IV inhibiting activity | ALTANA Pharma AG (DE) | 2006-04-26 | — | — | EP | disclosed |
| EP-1147089-B1 | PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | ALTANA PHARMA AG (DE) | 2005-12-07 | — | — | EP | disclosed |
| US-6476025-B1 | Phenylphennanthridines with PDE-IV inhibiting activity | ALTANA PHARMA AG (DE) | 2002-11-05 | — | — | US | disclosed |
| EP-1147089-A1 | PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000042020-A1 | PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281745-A1 | Use of pde4 inhibitors for the treatment of diabetes mellitus | PDE4A, PDE4B, PDE12 | PDE4A 1/4885PDE4D 4/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.